Kabiven (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The amino acids in Kabiven are directly delivered into the bloodstream, where they are taken up by cells for protein synthesis, tissue repair, and metabolic processes. This bypasses the digestive system, ensuring rapid availability of nutrients for patients who cannot eat or absorb nutrients normally.

The dose of Kabiven is individualized by the prescribing clinician based on the patient’s weight, metabolic needs, and clinical condition. Dosage calculations consider factors such as protein requirements, renal and hepatic function, and overall fluid balance.

The safety of Kabiven in pregnancy or lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Kabiven, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kabiven provides a balanced blend of ten essential amino acids in a single sterile solution, matching the composition recommended for adult parenteral nutrition. Compared with multi‑component TPN kits, Kabiven simplifies formulation by delivering a ready‑to‑use amino acid component, reducing preparation time and potential for mixing errors.

Kabiven must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particulate matter.

Kabiven is administered intravenously as an infusion, typically added to a total parenteral nutrition bag or given as a separate amino‑acid infusion. The rate and volume are set by the prescribing clinician and monitored by the healthcare team to ensure appropriate nutrient delivery.

Serious risks include severe allergic reactions (anaphylaxis), metabolic acidosis, and thrombophlebitis at the infusion site. Patients should be monitored for signs of hypersensitivity, changes in acid‑base balance, and catheter‑related complications during and after infusion.

Kabiven should be avoided in patients with known hypersensitivity to any of its amino acid components, in those with uncontrolled hyperkalemia, and in individuals with severe hepatic failure unless dosage adjustments are made. Clinical judgment is required for each case.